Alembic Pharmaceuticals has reported results for third quarter ended December 31, 2011.
The company has posted a rise of 15% in its net sales at Rs 383 crore for the quarter ended December 31, 2011 as compared to Rs 332 crore in corresponding quarter last year. The profit before tax was up by 18% at Rs 53.54 crore for the quarter under review as compared to Rs 45.40 crore in corresponding quarter last year.
Domestic formulations were up 8% at Rs 199 crore against Rs 184 crore in corresponding quarter last year. International generics were up by 13% to Rs 58 crore compared to Rs 52 crore last year.
The company has received approval for 2 ANDA in current quarter while 3 DMF’s were filed during the quarter.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1654.70 |
| Dr. Reddys Lab | 1232.00 |
| Cipla | 1229.60 |
| Zydus Lifesciences | 915.45 |
| Lupin | 2332.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: